PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

montelukast Side Effects

The reactions most often reported to the FDA for montelukast (also sold as Singulair), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

78,359
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2002 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of montelukast come from 78,359 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 78,359 reports to the FDA Adverse Event Reporting System (FAERS) for montelukast (Singulair): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

78,359

Reports Mentioning Death

3,777

4.8% of reports — not proof the medicine caused the death

Hospitalizations

21,518

27.5% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

DYSPNOEA
7,723
ASTHMA
7,439
FATIGUE
5,505
HEADACHE
4,786
COUGH
4,617
NAUSEA
4,214
PNEUMONIA
3,835
PAIN
3,602
ANXIETY
3,466
DIARRHOEA
3,414
WHEEZING
3,264
MALAISE
2,946
DIZZINESS
2,922
PRURITUS
2,900
RASH
2,866
VOMITING
2,682
ARTHRALGIA
2,494
PYREXIA
2,423

Who Reports Side Effects

Gender Distribution

Female 48,242 (67%)
Male 23,173 (32%)
Unknown 62

Age Distribution

0-17 5,513 (11%)
18-44 9,385 (18%)
45-64 18,237 (35%)
65-74 10,797 (21%)
75+ 7,713 (15%)

Reporting Trend by Year

2002 2025

Reactions in Death Reports

Top reactions reported in 3,777 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 1,714
PNEUMONIA 290
ASTHMA 258
DYSPNOEA 253
FATIGUE 221
PYREXIA 215
COMPLETED SUICIDE 214
HEADACHE 177
PAIN 167
ACUTE KIDNEY INJURY 160
NAUSEA 153
CONDITION AGGRAVATED 151
HYPERTENSION 143
CARDIAC ARREST 138
FLUID RETENTION 134
RESPIRATORY FAILURE 134
ERYTHEMA 133
CONSTIPATION 127

Reactions in Hospitalization Reports

Top reactions in 21,518 reports where hospitalization was an outcome.

Reaction Reports
DYSPNOEA 3,501
ASTHMA 3,138
PNEUMONIA 2,487
COUGH 1,699
WHEEZING 1,572
FATIGUE 1,556
HEADACHE 1,311
NAUSEA 1,266
PYREXIA 1,149
FALL 1,136
DIARRHOEA 1,105
MALAISE 1,085
VOMITING 1,019
PAIN 1,015
THERAPEUTIC PRODUCT EFFECT INCOMPLETE 945
ASTHENIA 901
HOSPITALISATION 863
DIZZINESS 854

Compare montelukast vs aclidinium →

What the FAERS Data Reveals About montelukast Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 78,359 voluntary reports linked to montelukast and its brand equivalents (Singulair), spanning 2002 through 2025. Of those, 3,777 (4.8%) listed death as an outcome and 21,518 (27.5%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 67% were female and 32% male; age distribution skews toward 45-64, with 18,237 reports in that bracket. The single most reported reaction is dyspnoea with 7,723 submissions, followed by asthma and fatigue.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.